ViiV to trial twice-yearly HIV antibody dosing after Phase IIb success
The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
Rolling Out15h
9 Health warnings your skin is trying to tell you
Your skin holds vital clues about your health. From thyroid issues to heart problems, discover what your skin is trying to ...
Medical Dialogues13h
Indian Case Study Supports Liquid Nitrogen as a Safe and Painless Gingival Depigmentation Technique
India: A recent case report published in the Cureus Journal has highlighted the effectiveness of liquid nitrogen cryotherapy ...
Le Lézard6h
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepointNo anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood ...
News-Medical.Net on MSN17h
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.